Orexo AB Announces Decision to Explore Strategic Alternatives for Commercialization in the U.S.

UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo (STO:ORX), a Swedish specialty pharmaceutical company with a focus on innovative sublingual drug delivery technologies, today announced that it has retained Guggenheim Securities, LLC as its financial advisor to assist in the Company’s review and evaluation of a full range of strategic alternatives. The Board of Directors initiated this review in conjunction with the Company’s ongoing evaluation of its US commercial plan, with the aim of enhancing both commercial prospects for the Company’s products and shareholder value.